Assessment of Effect and Safety of Ripasudil (0.4%) in patients of Primary Open Angle Glaucoma / Ocular Hypertension
العنوان: | Assessment of Effect and Safety of Ripasudil (0.4%) in patients of Primary Open Angle Glaucoma / Ocular Hypertension |
---|---|
المؤلفون: | Ishwar Singh, Harsimran Singh, Talvir Sidhu, Neha Chhabra, Rohit Raina |
المصدر: | Annals of International Medical and Dental Research. 8:1-7 |
بيانات النشر: | Scholars Publisher, 2022. |
سنة النشر: | 2022 |
مصطلحات موضوعية: | Automotive Engineering |
الوصف: | Background: The aim is to evaluate the intraocular pressure-lowering efficacy and tolerability of Ripasudil (0.4%) ophthalmic solution in patients of primary open-angle glaucoma/ocular hypertension.Material & Methods:In this prospective, interventional, single-arm, open-label study, 50 patients of POAG/ocular hypertension attending the Outpatient Department of Ophthalmology, Government Medical College, Patiala were included.Results:Mean value of numerical change in IOP at four weeks, at eight weeks, at twelve weeks in IOP were 3.61 ± 2.05, 3.98 ± 1.47, 4.44 ± 1.53 respectively. Among side effects, conjunctival hyperemia, blepharitis, and allergic conjunctivitis were reported among 62%, 10%, and 8% of the subjects at four weeks. Final results after 12 weeks showed that only conjunctival hyperemia was reported as a side effect among 16% of the subjects. Conclusions:Our present study showed significant IOP-lowering effects and safety of ripasudil (0.4%) over 12 weeks in patients with primary open-angle glaucoma/ocular hypertension. For the treatment of glaucoma and OHT, ripasudil is regarded as a possible second-line choice in spite of the high occurrence of conjunctival hyperemia. |
تدمد: | 2395-2822 2395-2814 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::6d1d999a5393c496de9ab437ac201989 https://doi.org/10.53339/aimdr.2022.8.3.1 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi...........6d1d999a5393c496de9ab437ac201989 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 23952822 23952814 |
---|